JP2018504418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504418A5 JP2018504418A5 JP2017539669A JP2017539669A JP2018504418A5 JP 2018504418 A5 JP2018504418 A5 JP 2018504418A5 JP 2017539669 A JP2017539669 A JP 2017539669A JP 2017539669 A JP2017539669 A JP 2017539669A JP 2018504418 A5 JP2018504418 A5 JP 2018504418A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- cancer
- compound
- represented
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 49
- 206010028980 Neoplasm Diseases 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 29
- 101800003838 Epidermal growth factor Proteins 0.000 claims 29
- 229940116977 epidermal growth factor Drugs 0.000 claims 29
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 24
- 229940121647 egfr inhibitor Drugs 0.000 claims 19
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 18
- 125000002252 acyl group Chemical group 0.000 claims 18
- 125000000524 functional group Chemical group 0.000 claims 18
- 150000004677 hydrates Chemical class 0.000 claims 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 18
- 230000003287 optical effect Effects 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 13
- 229960005395 cetuximab Drugs 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 229960001972 panitumumab Drugs 0.000 claims 11
- 229960001686 afatinib Drugs 0.000 claims 10
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 10
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 9
- 229960001433 erlotinib Drugs 0.000 claims 9
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 9
- 229960003278 osimertinib Drugs 0.000 claims 9
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 6
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000005787 hematologic cancer Diseases 0.000 claims 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 4
- 238000009169 immunotherapy Methods 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000003747 lymphoid leukemia Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 102100026882 Alpha-synuclein Human genes 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 108010065524 CD52 Antigen Proteins 0.000 claims 3
- 102000013135 CD52 Antigen Human genes 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims 2
- 229950004272 brigatinib Drugs 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- 229950008835 neratinib Drugs 0.000 claims 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 2
- 229960002450 ofatumumab Drugs 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 230000001235 sensitizing effect Effects 0.000 claims 2
- 229960005267 tositumomab Drugs 0.000 claims 2
- 229960000241 vandetanib Drugs 0.000 claims 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 230000007761 synergistic anti-cancer Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 C*(C)c1c(C(NC(C2=C(*)c3c(*)c(*)c(*)c(*)c3*2)=S)=*)c(*)c(*)c(*)c1* Chemical compound C*(C)c1c(C(NC(C2=C(*)c3c(*)c(*)c(*)c(*)c3*2)=S)=*)c(*)c(*)c(*)c1* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021011512A JP7624700B2 (ja) | 2015-02-05 | 2021-01-27 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112257P | 2015-02-05 | 2015-02-05 | |
| US62/112,257 | 2015-02-05 | ||
| US201562136530P | 2015-03-22 | 2015-03-22 | |
| US62/136,530 | 2015-03-22 | ||
| PCT/IL2016/050134 WO2016125169A1 (en) | 2015-02-05 | 2016-02-04 | Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021011512A Division JP7624700B2 (ja) | 2015-02-05 | 2021-01-27 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018504418A JP2018504418A (ja) | 2018-02-15 |
| JP2018504418A5 true JP2018504418A5 (enExample) | 2019-03-14 |
Family
ID=56563560
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539669A Pending JP2018504418A (ja) | 2015-02-05 | 2016-02-04 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
| JP2021011512A Active JP7624700B2 (ja) | 2015-02-05 | 2021-01-27 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
| JP2023027482A Pending JP2023062187A (ja) | 2015-02-05 | 2023-02-24 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021011512A Active JP7624700B2 (ja) | 2015-02-05 | 2021-01-27 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
| JP2023027482A Pending JP2023062187A (ja) | 2015-02-05 | 2023-02-24 | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10912745B2 (enExample) |
| EP (2) | EP3253733B1 (enExample) |
| JP (3) | JP2018504418A (enExample) |
| KR (1) | KR20170109589A (enExample) |
| CN (3) | CN107250108B (enExample) |
| AU (2) | AU2016213972B2 (enExample) |
| ES (2) | ES3064856T3 (enExample) |
| IL (2) | IL253797B (enExample) |
| WO (1) | WO2016125169A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250007056A (ko) | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| US20200369607A1 (en) * | 2017-11-16 | 2020-11-26 | Tyrnovo Ltd. | Combinations of irs/stat3 dual modulators and anti pd-1/pd-l1 antibodies for treating cancer |
| AU2018368639B2 (en) * | 2017-11-20 | 2025-02-27 | Tolremo Therapeutics Ag | Diagnostic method |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| JP7386174B2 (ja) * | 2018-03-27 | 2023-11-24 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｈｅｒ２エクソン１９変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
| BR112021000065A2 (pt) | 2018-07-10 | 2021-04-06 | Sanofi | Terapias de combinação contra câncer direcionando cd38 e tgf-beta |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| AU2019338207B2 (en) * | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| US20220008409A1 (en) * | 2018-09-18 | 2022-01-13 | Kabushiki Kaisha Yakult Honsha | Cancer combination therapy using quinoline carboxamide derivative |
| CN109675040B (zh) * | 2018-12-31 | 2021-07-30 | 清华大学 | 治疗乳腺癌的组合物及其应用 |
| US12629375B2 (en) | 2019-03-29 | 2026-05-19 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions |
| KR102980990B1 (ko) | 2019-04-05 | 2026-06-25 | 카이메라 쎄라퓨틱스 인코포레이티드 | Stat 분해제 및 이의 용도 |
| US20220218731A1 (en) * | 2019-05-22 | 2022-07-14 | Clear Creek Bio, Inc. | Combination therapies for cancer treatment |
| CN115466205B (zh) * | 2021-11-04 | 2023-10-24 | 特尔诺沃有限公司 | 分离的3-（2-溴-3,4-二羟基-苯基）-n-（3,4,5-三羟基-苄基）-硫代丙烯酰胺的反式异构体 |
| US20250011790A1 (en) * | 2021-11-11 | 2025-01-09 | Vanderbilt University | Combined targeting of stat3 and ulki to treat glioblastoma |
| KR20240086554A (ko) | 2022-12-09 | 2024-06-18 | 재단법인대구경북과학기술원 | 올무티닙을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| CN1155977A (zh) | 1995-08-28 | 1997-08-06 | 化学工业部沈阳化工研究院 | 含氟二苯基丙烯酰胺类杀菌剂 |
| CN1043720C (zh) | 1995-08-28 | 1999-06-23 | 化学工业部沈阳化工研究院 | 含氟二苯基丙烯酰胺类杀菌剂 |
| WO1997045111A1 (en) | 1996-05-24 | 1997-12-04 | Neurosearch A/S | Phenyl derivatives useful as blockers of chloride channels |
| EP0906273B1 (en) | 1996-05-24 | 2002-10-16 | Neurosearch A/S | Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers |
| US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| US6020332A (en) | 1997-02-20 | 2000-02-01 | Shenyang Research Institute Of Chemical Industry | Fluorine-containing diphenyl acrylamide antimicrobial agents |
| DE69718288T2 (de) | 1997-02-21 | 2003-07-31 | Shenyang Research Institute Of Chemical Industry, Shenyang Liaoning | Fluorine enthaltende Diphenylacrylamid Microbizide |
| AU1457299A (en) | 1997-11-12 | 1999-05-31 | Ariad Pharmaceuticals, Inc. | Novel signal transduction inhibitors, compositions containing them |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6455587B1 (en) | 2000-03-15 | 2002-09-24 | Pharmacor Inc. | Amino acid derivatives as HIV aspartyl protease inhibitors |
| EP1482983A4 (en) | 2001-06-14 | 2006-07-12 | Yissum Res Dev Co | NON-MYELOABLATIVE AND TOLEROGENIC TREATMENT BY TYRPHOSTINES |
| DE60211746D1 (de) | 2001-11-21 | 2006-06-29 | Elan Pharm Inc | Aminosäurederivate zur behandlung der alzheimer-krankheit |
| WO2003053425A1 (en) | 2001-12-10 | 2003-07-03 | Yansheng Du | Treatment of neurodegenerative and cardiovascular disorders |
| MXPA03000966A (es) | 2002-02-28 | 2003-09-04 | Pfizer Prod Inc | Agentes antidiabeticos. |
| PT1511710E (pt) | 2002-05-31 | 2014-02-26 | Proteotech Inc | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson |
| US20040209930A1 (en) * | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US20060047171A1 (en) | 2003-12-22 | 2006-03-02 | Harold Meckler | Catalytic hydrogenation of nitriles to produce capsaicinoid derivatives and amine compounds, and methods for purifying and obtaining the polymorphs thereof |
| KR100683274B1 (ko) | 2004-02-12 | 2007-02-15 | 에스케이케미칼주식회사 | 치환된 벤조피란 화합물의 제조방법 |
| WO2007072041A1 (en) | 2005-12-23 | 2007-06-28 | Astex Therapeutics Limited | Therapeutic compounds |
| WO2008028314A1 (fr) | 2006-08-07 | 2008-03-13 | Lotus Pharmaceutical Co., Ltd. | Dérivés de catéchol, composition et application associées |
| US20120083528A1 (en) | 2006-12-04 | 2012-04-05 | Novotyr Therapeutics Ltd. | Novel protein kinase modulators and therapeutic uses thereof |
| US8058309B2 (en) | 2006-12-04 | 2011-11-15 | Novotyr Therapeutics Ltd. | Protein kinase modulators and therapeutic uses thereof |
| US8637575B2 (en) | 2008-06-05 | 2014-01-28 | Novotyr Therapeutics Ltd. | Modulators of protein kinase signaling |
| WO2012090204A1 (en) * | 2010-12-27 | 2012-07-05 | Novotyr Therapeutics Ltd. | 2 - (2 - phenylethenyl) - 1, 3 -benzothiazine derivatives useful for the treatment cancer |
| WO2012117396A1 (en) * | 2011-03-01 | 2012-09-07 | Novotyr Therapeutics Ltd | Tyrphostin derivative in combination with cytotoxic compounds for treating cancer |
| US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
| US20160120848A1 (en) | 2013-05-21 | 2016-05-05 | Synta Pharmaceuticals Corp. | Specific cancer treatment regimes with ganetespib |
-
2016
- 2016-02-04 CN CN201680008809.6A patent/CN107250108B/zh active Active
- 2016-02-04 WO PCT/IL2016/050134 patent/WO2016125169A1/en not_active Ceased
- 2016-02-04 ES ES20168234T patent/ES3064856T3/es active Active
- 2016-02-04 AU AU2016213972A patent/AU2016213972B2/en active Active
- 2016-02-04 EP EP16746247.2A patent/EP3253733B1/en active Active
- 2016-02-04 JP JP2017539669A patent/JP2018504418A/ja active Pending
- 2016-02-04 US US15/548,915 patent/US10912745B2/en active Active
- 2016-02-04 CN CN202011245500.3A patent/CN112353938A/zh active Pending
- 2016-02-04 CN CN202011245496.0A patent/CN112494653A/zh active Pending
- 2016-02-04 EP EP20168234.1A patent/EP3750530B1/en active Active
- 2016-02-04 KR KR1020177023283A patent/KR20170109589A/ko not_active Ceased
- 2016-02-04 ES ES16746247T patent/ES2808781T3/es active Active
-
2017
- 2017-08-02 IL IL253797A patent/IL253797B/en active IP Right Grant
-
2020
- 2020-10-08 AU AU2020250235A patent/AU2020250235A1/en not_active Abandoned
-
2021
- 2021-01-24 IL IL280378A patent/IL280378B/en unknown
- 2021-01-27 US US17/159,798 patent/US12201592B2/en active Active
- 2021-01-27 JP JP2021011512A patent/JP7624700B2/ja active Active
-
2023
- 2023-02-24 JP JP2023027482A patent/JP2023062187A/ja active Pending
-
2025
- 2025-01-02 US US19/007,840 patent/US20250134837A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nagelkerke et al. | Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy | |
| TWI794171B (zh) | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 | |
| JP2019501204A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2014034576A5 (enExample) | ||
| CN120285177A (zh) | Hdac抑制剂和pd-1抑制剂的组合疗法 | |
| JP2020536971A5 (enExample) | ||
| JP2018534289A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| JP2010522194A5 (enExample) | ||
| JP2009514881A5 (enExample) | ||
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| JP2014508782A5 (enExample) | ||
| US20180085341A1 (en) | Methods for treating cancer | |
| RU2013132018A (ru) | Применение производных пиримидина для лечения egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, направленным против членов семейства egfr | |
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| WO2018229130A1 (en) | Compounds for treating tnbc | |
| KR20210019116A (ko) | 카복시아미도트리아졸 오로테이트를 사용하여 화학치료제 및 표적화된 약물에 대해 내성을 획득한 암을 치료하기 위한 방법 및 조성물 | |
| JP2022502399A5 (enExample) | ||
| CN106255500B (zh) | 用于治疗癌症的新的头孢菌素衍生物 | |
| US10646464B2 (en) | Methods for treating cancer | |
| JP2021512046A5 (enExample) | ||
| RU2017105817A (ru) | Комбинированная терапия | |
| JP2019519573A (ja) | がんを処置するための方法 | |
| US20180250260A1 (en) | Methods for treating cancer |